KNSA — Kiniksa Pharmaceuticals International, plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1730430 ·
United Kingdom
Last close
$76.10
Market Cap
$3.67B
52W High
$82.94
52W Low
$35.20
ADV30
513,372
Next earnings
2026-10-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 243,600,000 | 131,959,000 | 27,194,000 | 25,432,000 | 896,110,000 | 175,677,000 | 241,961,000 |
| Mar 2026 | 214,266,000 | 117,893,000 | 29,267,000 | 22,592,000 | 825,280,000 | 189,952,000 | 219,593,000 |
| Dec 2025 | 202,127,000 | 111,152,000 | 19,768,000 | 14,199,000 | 763,633,000 | 165,596,000 | 196,027,000 |
| Sep 2025 | 180,855,000 | 97,291,000 | 24,021,000 | 18,435,000 | 712,333,000 | 174,858,000 | 176,950,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$184,965,000
Investing CF
$-239,065,000
Financing CF
$37,740,000
CapEx
$-2,128,000
Dividends Paid
—
Buybacks
$-11,055,000
EPS Diluted TTM
$0.97
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-414,114,000
Inventory
$70,930,000
Receivables
$23,490,000
ST Investments
$350,251,000
EBIT TTM
$100,250,000
Pretax Income TTM
$114,252,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$840,848,000
EBITDA
$102,041,000
Free Cash Flow
$126,144,248
Enterprise Value
$5,433,860,608
Total Cash
$525,928,000
Total Debt
$8,897,000
Shares Out
48,289,273
Trailing EPS
$0.99
Book Value
$8.39
ROE
14.0%
ROA
8.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 677,564,000 | 77,221,000 | 59,005,000 | 763,633,000 | 196,027,000 | 567,606,000 | 137,985,000 |
| Dec 2024 | 423,239,000 | -45,616,000 | -43,193,000 | 580,553,000 | 142,117,000 | 438,436,000 | 25,689,000 |
| Dec 2023 | 270,259,000 | -25,196,000 | 14,084,000 | 526,322,000 | 87,483,000 | 438,839,000 | 13,301,000 |
| Dec 2022 | 220,180,000 | 9,773,000 | 183,363,000 | 459,672,000 | 63,523,000 | 396,149,000 | 5,807,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.62
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $75.00 · spot: $76.10 · call volume: 49 · put volume: 35
Expected Move to 2026-11-20:
±$13.81
(18.15%) —
implied range
$62.29 –
$89.91
· ATM straddle on $75.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IDYA | IDEAYA Biosciences, Inc. | $3.69B | $38.22 | — |
| LEGN | Legend Biotech Corp | $3.62B | $18.62 | — |
| OGN | Organon & Co. | $3.61B | $13.73 | — |
| XENE | Xenon Pharmaceuticals Inc. | $3.56B | $36.72 | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $3.54B | $20.53 | — |
News headlines (Yahoo Finance, 1h cache)
Kiniksa Pharmaceuticals International (KNSA) On The ARCALYST Story And Whether Shares Look Fully Valued
2026-09-23 23:14 · Yahoo
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
2026-09-17 16:13 · Yahoo
Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat
2026-09-10 16:35 · Yahoo
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
2026-09-04 20:01 · Yahoo
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
2026-08-15 01:01 · Yahoo
Could Kiniksa Pharmaceuticals International (KNSA) Be 16% Overvalued After Raised 2026 Guidance?
2026-07-30 03:15 · Yahoo
Why Kiniksa Pharmaceuticals (KNSA) Is Up 29.6% After Raising 2026 Revenue Guidance And Advancing Pipeline
2026-07-29 22:08 · Yahoo
Kiniksa Reports Strong Q2 Results, Raises 2026 ARCALYST Sales Guidance
2026-07-28 14:09 · Yahoo
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights
2026-07-28 14:04 · Yahoo
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
2026-07-28 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.